Literature DB >> 1884737

Monitoring of the free concentration of cyclosporine in plasma in man.

A Lindholm1.   

Abstract

The free fraction of cyclosporine A (CsA) and its total plasma concentration as determined by HPLC(CsAT) were prospectively monitored in 66 recipients of renal transplants. The free CsA levels (CsAu) were calculated. The variability in free CsA levels was no less than for total CsAT levels. The correlation between CsAu and CsAT was high (r = 0.90). Both CsAT and CsAu covaried with serum triglycerides and apolipoprotein A1. Fourty-four of the 66 patients suffered acute rejection episodes on 69 occasions. CsAT and CSAu both decreased and to a similar extent at the occurrence of acute rejection (42% and 59% decrease, respectively; significant vs baseline. Not significant difference in decrease in CsAT vs CsAu). Acute nephrotoxicity occurred on 11 occasions in 10 patients. Both CsAT and CSAu were approximately twice as high at the time of acute nephrotoxicity as compared to one week previously. Both CsAT and CsAu were higher during the first month after transplantation in patients with than in patients without systemic infection. Thus, plasma CsAu gave no additional clinical information or guidance compared to CsAT in renal transplant recipients. Due to the complexity of its assay, which requires two consecutive analyses, there does not appear to be any need for routine monitoring of CsAu in renal transplant recipients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1884737     DOI: 10.1007/bf00279972

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Semi-automated high-performance liquid chromatographic determination of cyclosporine A in whole blood using one-step sample purification and column-switching.

Authors:  G Hamilton; E Roth; E Wallisch; F Tichy
Journal:  J Chromatogr       Date:  1985-06-14

2.  Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood.

Authors:  M Lemaire; J P Tillement
Journal:  J Pharm Pharmacol       Date:  1982-11       Impact factor: 3.765

3.  Minimal low dosage of cyclosporine therapy in renal transplantation by careful monitoring of high-performance liquid chromatography whole blood trough levels.

Authors:  K Uchida; N Yamada; A Orihara; Y Tominaga; Y Tanaka; S Hayashi; T Kondo; K Morozumi; M Satake; N Taira
Journal:  Transplant Proc       Date:  1988-04       Impact factor: 1.066

4.  High cyclosporin levels after bone marrow transplantation associated with hypertriglyceridaemia.

Authors:  J Nemunaitis; H J Deeg; G C Yee
Journal:  Lancet       Date:  1986-09-27       Impact factor: 79.321

5.  Comparative analyses of cyclosporine in whole blood and plasma by radioimmunoassay, fluorescence polarization immunoassay, and high-performance liquid chromatography.

Authors:  A Lindholm; S Henricsson
Journal:  Ther Drug Monit       Date:  1990-07       Impact factor: 3.681

6.  A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation.

Authors:  A Lindholm; R Dahlqvist; G G Groth; F Sjöqvist
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

7.  Blood-brain barrier transport of CI-912: single-passage equilibration of erythrocyte-borne drug.

Authors:  E M Cornford; K P Landon
Journal:  Ther Drug Monit       Date:  1985       Impact factor: 3.681

8.  Intra- and interindividual variability in the free fraction of cyclosporine in plasma in recipients of renal transplants.

Authors:  A Lindholm; S Henricsson
Journal:  Ther Drug Monit       Date:  1989-11       Impact factor: 3.681

9.  Cyclophilin: a specific cytosolic binding protein for cyclosporin A.

Authors:  R E Handschumacher; M W Harding; J Rice; R J Drugge; D W Speicher
Journal:  Science       Date:  1984-11-02       Impact factor: 47.728

10.  A radioimmunoassay to measure cyclosporin A in plasma and serum samples.

Authors:  P Donatsch; E Abisch; M Homberger; R Traber; M Trapp; R Voges
Journal:  J Immunoassay       Date:  1981
View more
  3 in total

Review 1.  Distribution of cyclosporin in organ transplant recipients.

Authors:  Fatemeh Akhlaghi; Andrew K Trull
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Therapeutic monitoring of cyclosporin--an update.

Authors:  A Lindholm
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients.

Authors:  Anisha E Mendonza; Reginald Y Gohh; Fatemeh Akhlaghi
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.